These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Oxidative stress and inflammation in Parkinson's disease: is there a causal link? Hald A; Lotharius J Exp Neurol; 2005 Jun; 193(2):279-90. PubMed ID: 15869932 [TBL] [Abstract][Full Text] [Related]
23. Neuroinflammation and oxidative stress: co-conspirators in the pathology of Parkinson's disease. Taylor JM; Main BS; Crack PJ Neurochem Int; 2013 Apr; 62(5):803-19. PubMed ID: 23291248 [TBL] [Abstract][Full Text] [Related]
25. Reduced BDNF mRNA expression in the Parkinson's disease substantia nigra. Howells DW; Porritt MJ; Wong JY; Batchelor PE; Kalnins R; Hughes AJ; Donnan GA Exp Neurol; 2000 Nov; 166(1):127-35. PubMed ID: 11031089 [TBL] [Abstract][Full Text] [Related]
26. The influence of microglia on the pathogenesis of Parkinson's disease. Long-Smith CM; Sullivan AM; Nolan YM Prog Neurobiol; 2009 Nov; 89(3):277-87. PubMed ID: 19686799 [TBL] [Abstract][Full Text] [Related]
27. How to improve neuroprotection in Parkinson's disease? Hirsch EC Parkinsonism Relat Disord; 2007; 13 Suppl 3():S332-5. PubMed ID: 18267260 [TBL] [Abstract][Full Text] [Related]
28. Oestrogen and nigrostriatal dopaminergic neurodegeneration: animal models and clinical reports of Parkinson's disease. Liu B; Dluzen DE Clin Exp Pharmacol Physiol; 2007 Jul; 34(7):555-65. PubMed ID: 17581209 [TBL] [Abstract][Full Text] [Related]
29. A new ethyladenine antagonist of adenosine A(2A) receptors: behavioral and biochemical characterization as an antiparkinsonian drug. Pinna A; Tronci E; Schintu N; Simola N; Volpini R; Pontis S; Cristalli G; Morelli M Neuropharmacology; 2010 Mar; 58(3):613-23. PubMed ID: 19951715 [TBL] [Abstract][Full Text] [Related]
30. Role of p38 and inducible nitric oxide synthase in the in vivo dopaminergic cells' degeneration induced by inflammatory processes after lipopolysaccharide injection. Ruano D; Revilla E; Gavilán MP; Vizuete ML; Pintado C; Vitorica J; Castaño A Neuroscience; 2006 Jul; 140(4):1157-68. PubMed ID: 16713109 [TBL] [Abstract][Full Text] [Related]
32. Targeting metabolic inflammation in Parkinson's disease: implications for prospective therapeutic strategies. Lu M; Hu G Clin Exp Pharmacol Physiol; 2012 Jun; 39(6):577-85. PubMed ID: 22126374 [TBL] [Abstract][Full Text] [Related]
33. The contributions of antioxidant activity of lipoic acid in reducing neurogenerative progression of Parkinson's disease: a review. De Araújo DP; Lobato Rde F; Cavalcanti JR; Sampaio LR; Araújo PV; Silva MC; Neves KR; Fonteles MM; Sousa FC; Vasconcelos SM Int J Neurosci; 2011 Feb; 121(2):51-7. PubMed ID: 21126109 [TBL] [Abstract][Full Text] [Related]
34. Inflammation induces mitochondrial dysfunction and dopaminergic neurodegeneration in the nigrostriatal system. Hunter RL; Dragicevic N; Seifert K; Choi DY; Liu M; Kim HC; Cass WA; Sullivan PG; Bing G J Neurochem; 2007 Mar; 100(5):1375-86. PubMed ID: 17254027 [TBL] [Abstract][Full Text] [Related]
36. Glatiramer acetate could be a potential therapeutic agent for Parkinson's disease through its neuroprotective and anti-inflammatory effects. Tsai SJ Med Hypotheses; 2007; 69(6):1219-21. PubMed ID: 17548170 [TBL] [Abstract][Full Text] [Related]
37. Novel role of aquaporin-4 in CD4+ CD25+ T regulatory cell development and severity of Parkinson's disease. Chi Y; Fan Y; He L; Liu W; Wen X; Zhou S; Wang X; Zhang C; Kong H; Sonoda L; Tripathi P; Li CJ; Yu MS; Su C; Hu G Aging Cell; 2011 Jun; 10(3):368-82. PubMed ID: 21255222 [TBL] [Abstract][Full Text] [Related]
38. Role of ICAM-1 in persisting inflammation in Parkinson disease and MPTP monkeys. Miklossy J; Doudet DD; Schwab C; Yu S; McGeer EG; McGeer PL Exp Neurol; 2006 Feb; 197(2):275-83. PubMed ID: 16336966 [TBL] [Abstract][Full Text] [Related]
39. Pathogenesis of nigral cell death in Parkinson's disease. Przedborski S Parkinsonism Relat Disord; 2005 Jun; 11 Suppl 1():S3-7. PubMed ID: 15885625 [TBL] [Abstract][Full Text] [Related]
40. New evidences for fractalkine/CX3CL1 involved in substantia nigral microglial activation and behavioral changes in a rat model of Parkinson's disease. Shan S; Hong-Min T; Yi F; Jun-Peng G; Yue F; Yan-Hong T; Yun-Ke Y; Wen-Wei L; Xiang-Yu W; Jun M; Guo-Hua W; Ya-Ling H; Hua-Wei L; Ding-Fang C Neurobiol Aging; 2011 Mar; 32(3):443-58. PubMed ID: 19368990 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]